Author Archives: Colin Hayward

Meet us at PCT Europe 2018! If the United Kingdom’s plan to exit the European Union evokes thoughts of a perilous road of steep grades and switchbacks, you’re pretty well attuned to the politically and commercially fraught process known as Brexit. More than two years after British voters elected to split from the EU, itRead more

Over the past few years, there has been a dramatic increase in the use of genetically modified cells for cancer immunotherapy, including chimeric antigen receptor (CAR)-T cells, recombinant T-cell receptor T cells and genetically modified CD34+ cells for the treatment of hematological malignancies. Clinical trials of immuno-gene therapeutics are becoming increasingly common, and regulatory guidelinesRead more

This week, we get a Tales from the Road two-for-one, from Dr. Colin Hayward, our Chief Medical Officer, who went to the Oxford Biotech Network Awards one week, and the ESMO Conference the next. Have a look: OBN Premier Research had the opportunity once again to support the Oxford Biotech Network (OBN) awards night. ThatRead more

No more posts
Phone Us Now
Email Us Now